MTE #6: New Hepatitis B Virus and Hepatitis D Virus Treatments Including Drugs in Development (Ticketed)

Nov 06 2026

Convention Center: Room 1F

7:00 AM - 7:45 AM

Ticketed Event

CE Credits

World Class Speakers

Robert Gish

Discussion Leader

Scott Fung

Discussion Leader

Description

The recent wealth of new clinical trial data addressing the treatment of persons living with hepatitis B virus (HBV) moninfection, and HBV and hepatitis D virus (HDV) coinfection has fueled excitement among clinicians regarding the prospect of cures for HBV infection and HBV/HDV coinfection. This expert session focuses on new treatments for HBV monoinfection and HBV/HDV coinfection including:

Capsid assembly modulators (CAMs; eg, pevifoscorvir)
Small interfereing RNA (SiRNA; eg, elebsiran) and antisense oligonucleotides (ASO; eg, bepirovirsen)
Monoclonal hepatitis B surface (HBs) antibodies (eg, tobevibart)
Gene editing nucleases (eg, PBGENE-HBV)
Other novel therapies

Discussion leaders present a representative case and integrate new clinical trial data to illustrate the role of newer therapies for persons living with HBV or HBV/HDV infection.

Objectives

Review the efficacy and safety of new agents in development for hepatitis B virus (HBV) infection cure.
Discuss the efficacy and safety of new agents in development for hepatitis D virus (HDV) infection cure.
Evaluate agents in combination for the treatment of HBV/HDV coinfection.
List the remaining barriers to HBV and HDV infection cure.